Fouad Namouni, MD
The combination of nivolumab (Opdivo) plus radiation therapy compared with temozolomide did not improve overall survival (OS) in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM), missing the coprimary endpoint of the phase III CheckMate-498 trial.1
The ongoing phase III CheckMate-548 trial (NCT02667587) is evaluating nivolumab in combination with radiation therapy and temozolomide in patients with newly diagnosed MGMT-methylated GBM.
- Bristol-Myers Squibb Announces Phase 3 CheckMate-498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme. Bristol-Myers Squibb. Published May 9, 2019. https://bit.ly/2V9ceag. Accessed May 9, 2019.
- Reardon DA, Omuro A Brandes AA, et al. Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncol. 2017;19(3):iii21. doi: 10.1093/neuonc/nox036.071.
... to read the full story